ACCEPTED MANUSCRIPT
8
Tetrahedron
-3.86. MS (EI): m/z (%) 418 (20) [M+], 361 (100). Anal. Calcd
4.4.4. 4-(4-((tert-Butyldimethylsilyl)oxy)-2-(furan-2-yl)thiazol-5-
1
for C19H22N2O3S2Si: C, 54.52; H, 5.30; N, 6.69; S, 15.32. Found:
C, 54.32; H, 5.33; N, 7.01; S, 15.58.
yl)aniline (3d). Yellow solid (1.40 g, 75%). MP 93.0-93.3 °C. H
NMR (400 MHz, CDCl3): δ = 7.58-7.52 (m, 2H), 7.45 (dd, J 1.7,
0.6 Hz, 1H), 6.86 (dd, J 3.4, 0.6 Hz, 1H), 6.73-6.66 (m, 2H), 6.50
(dd, J 3.4, 1.8 Hz, 1H), 3.72 (s, 2H), 1.02 (s, J 2.8 Hz, 9H), 0.34
(s, J 3.2 Hz, 6H). 13C NMR (100 MHz, CDCl3): δ = 154.88,
149.81, 148.16, 145.18, 143.01, 128.14, 122.42, 115.26, 112.81,
112.26, 107.62, 26.13, 18.32, -3.91. MS (EI): m/z (%) 372 (70)
[M+], 315 (100). Anal. Calcd for C19H24N2O2SSi: C, 61.25; H,
6.49; N, 7.52; S, 8.61. Found: C, 61.45; H, 6.59; N, 7.36; S, 8.85.
4.3.4. 4-((tert-Butyldimethylsilyl)oxy)-2-(furan-2-yl)-5-(4-
nitrophenyl)thiazole (2d). Brown thick needles (2.50 g, 62%).
MP 166.0-166.3 °C. H NMR (250 MHz, CDCl3): δ = 8.26-8.15
(m, 2H), 7.95-7.81 (m, 2H), 7.52 (d, J 1.5 Hz, 1H), 6.98 (d, J
3.5 Hz, 1H), 6.56 (dd, J 3.4, 1.7 Hz, 1H), 1.05 (s, 9H), 0.40 (s,
6H). 13C NMR (63 MHz, CDCl3): δ = 158.47, 152.51, 149.11,
145.36, 144.22, 139.14, 126.37, 124.24, 112.67, 109.75, 109.69,
26.09, 18.32, -3.87. MS (EI): m/z (%) 402 (50) [M+], 345 (100).
Anal. Calcd for C19H22N2O4SSi: C, 56.69; H, 5.51; N, 6.96; S,
7.97. Found: C, 56.71; H, 5.49; N, 6.87; S, 7.66.
1
4.5. General procedure for the preparation of the pyridinium
tetrafluoroborate salts
To a suspension of the corresponding amine (2.0 mmol) and
2,4,6-triphenylpyrylium tetrafluoroborate (2.0 mmol) in EtOH
(20 mL) in a round bottle flask was added Et3N (2.0 mmol). The
mixture turned deep brown while the educts dissolved and was
stirred for 30 min at r.t. followed by the addition of AcOH
(4.0 mmol) and heating under reflux conditions for additional
2 h. The product precipitated during the reaction. The product
was dissolved directly in the flask with little acetone at the reflux
temperature after the reaction was finished (no further precipitate
occurred). After cooling down to r.t. the product crystallized as a
yellow solid which was filtered off, washed with cold EtOH and
pentane and dried in vacuo.
4.4. General procedure for the reduction of the nitro group to
the corresponding amines
The corresponding nitro compound (5.0 mmol) was dissolved
in THF (50 mL) in an autoclave (Büchi AG, model: miniclave
steel) and a spate Pd/C was added. Hydrogen was applied (max.
10 bar) under continuous stirring at r.t, or if the reaction proceeds
slow, at slightly elevated temperature (max. 50 °C). After the
reaction was finished (3-10 h) as indicated by TLC (silica,
CHCl3; the educts elute at the front, while the amines do not
elute) the catalyst was filtered off and the remaining solution was
concentrated in vacuo. A short gel filtration (silica, CHCl3 to
CHCl3/EtOAc 2:1) yielded the amines as yellow solids or oils
which solidify after a while.
4.5.1. 1-(4-(4-Hydroxy-2-(pyridin-2-yl)thiazol-5-yl)phenyl)-2,4,6-
triphenylpyridin-1-ium tetrafluoroborate (4a). Orange crystalline
solid (0.93 g, 72%). MP >255 °C decompose. 1H NMR
(400 MHz, DMSO-d6): δ = 8.65 (s, 2H), 8.60 (d, J = 4.7 Hz, 1H),
8.34 (d, J = 6.9 Hz, 2H), 8.00-7.91 (m, 2H), 7.74-7.64 (m, 3H),
7.57 (d, J = 8.7 Hz, 2H), 7.53-7.35 (m, 13H), 4.34 (s, 1H). 13C
NMR (100 MHz, DMSO-d6): 161.89, 159.99, 156.44, 155.51,
149.75, 137.80, 136.49, 133.40, 133.07, 132.54, 130.03, 129.72,
129.08, 128.79, 128.19, 125.27, 125.19, 125.14, 118.64, 108.23.
4.4.1. 4-(4-((tert-Butyldimethylsilyl)oxy)-2-(pyridin-2-yl)thiazol-
5-yl)aniline (3a). Yellow solid (1.59 g, 83%). MP 132.9-
1
133.2 °C. H NMR (250 MHz, CDCl3): δ = 8.56 (d, J 4.8 Hz,
1H), 8.02 (d, J 7.9 Hz, 1H), 7.74 (td, J 7.8, 1.7 Hz, 1H), 7.61 (d,
J 8.6 Hz, 2H), 7.22 (m, 1H), 6.70 (d, J 8.6 Hz, 2H), 3.74 (s, 2H),
1.04 (s, 9H), 0.37 (s, 6H). 13C NMR (63 MHz, CDCl3): δ =
157.97, 155.23, 151.74, 149.46, 145.46, 136.93, 128.35, 123.80,
122.56, 118.91, 116.71, 115.24, 77.16, 26.14, 18.35, -3.84. MS
(EI): m/z (%) 383 (100) [M+], 326 (90). Anal. Calcd for
C19H22N2O4SSi: C, 62.62; H, 6.57; N, 10.95; S, 8.36. Found: C,
62.69; H, 6.89; N, 10.94; S 8.11.
−
MS (EI): m/z (%) 559 (<1) [M-BF4 ]+, 426 (<1), 307 (100). Anal.
Calcd for C37H26BF4N3OS: C, 67.54; H, 4.65; N, 6.06; S, 4.62.
Found: C, 67.50; H, 4.72; N, 6.12; S, 4.56.
4.5.2. 1-(4-(4-Hydroxy-2-(pyrazin-2-yl)thiazol-5-yl)phenyl)-
2,4,6-triphenylpyridin-1-ium tetrafluoroborate (4b). Yellow
crystalline solid (0.95 g, 73%). MP >250 °C decompose. 1H
1
4.4.2. 4-(4-((tert-Butyldimethylsilyl)oxy)-2-(pyrazin-2-yl)thiazol-
NMR (400 MHz, DMSO-d6): H NMR (400 MHz, DMSO-d6): δ
5-yl)aniline (3b). Red orange solid (1.52 g, 79%). MP 155.0-
= 12.27 (s, 1H), 9.17 (d, J = 15.4 Hz, 1H), 8.81-8.60 (m, 4H),
8.37 (d, J = 7.1 Hz, 2H), 7.75-7.64 (m, 3H), 7.61 (d, J = 8.6 Hz,
2H), 7.56-7.45 (m, 6H), 7.45-7.32 (m, 6H). 13C NMR (100 MHz,
DMSO-d6): 160.26, 159.05, 156.42, 155.52, 145.87, 145.26,
144.63, 139.87, 136.90, 133.42, 133.10, 132.91, 132.57, 130.05,
129.75, 129.20, 128.85, 128.23, 125.39, 125.19, 109.55. MS (EI):
1
155.2 °C. H NMR (250 MHz, CDCl3): δ = 9.27 (d, J 1.3 Hz,
1H), 8.50-8.45 (m, 2H), 7.64-7.57 (m, 2H), 6.73-6.66 (m, 2H),
3.77 (s, 2H), 1.04 (s, 9H), 0.38 (s, 6H). 13C NMR (63 MHz,
CDCl3): δ = 155.66, 154.73, 147.11, 145.85, 144.09, 143.81,
140.99, 128.40, 121.88, 118.23, 115.13, 26.05, 18.28, -3.92. MS
(EI): m/z (%) 384 (90) [M+], 327 (100). Anal. Calcd for
C19H24N4OSSi: C, 59.34; H, 6.29; N, 14.57; S, 8.34. Found: C,
59.31; H, 6.29; N, 14.53; S, 8.17.
−
m/z (%) 561.1 (1) [M-BF4 ]+, 427 (1), 307 (100).
C36H25BF4N4OS: C, 66.68; H, 3.89; N, 8.64; S, 4.94. Found: C,
66.96; H, 3.90; N, 8.77; S, 4.55.
4.4.3. 4-(4-((tert-Butyldimethylsilyl)oxy)-2-(thiophen-2-
4.5.3. 1-(4-(4-Hydroxy-2-(thiophen-2-yl)thiazol-5-yl)phenyl)-
2,4,6-triphenylpyridin-1-ium tetrafluoroborate (4c). Yellow-
orange solid (0.60 g, 46%). MP 262.0-263.5 °C. 1H NMR
(400 MHz, DMSO-d6): δ = 12.06 (s, 1H), 8.66 (s, 2H), 8.36 (d, J
= 8.0 Hz, 2H), 7.74 (dd, J = 5.1 Hz, 1.0 Hz, 1H), 7.72-7.63 (m,
3H), 7.60 (dd, J = 3.7 Hz, 1.0 Hz, 1H), 7.55-7.30 (m, 14H), 7.17
(dd, J = 5.0 Hz, 3.8 Hz, 1H). 13C NMR (100 MHz, DMSO-d6):
159.06, 156.44, 155.48, 155.34, 136.27, 136.26, 133.42, 133.12,
133.08, 132.56, 130.03, 129.75, 129.50, 129.11, 128.84, 128.77,
128.20, 127.14, 125.18, 124.83, 104.64. MS (EI): m/z (%) 565
yl)thiazol-5-yl)aniline (3c). Orange solid (1.75 g, 88%). MP
1
175.0-175.5 °C. H NMR (250 MHz, CDCl3): δ = 7.58-7.49 (m,
2H), 7.40 (dd, J = 3.7 Hz, 1.0 Hz, 1H), 7.31 (dd, J = 5.0 Hz,
0.9 Hz, 1H), 7.04 (dd, J = 5.0 Hz, 3.7 Hz, 1H), 6.73-6.65 (m,
2H), 1.03 (s, 9H), 0.36 (s, 6H). 13C NMR (63 MHz, CDCl3): δ =
154.29, 51.87, 145.16, 138.58, 128.06, 127.92, 126.89, 124.83,
122.43, 115.26, 112.47, 26.17, 18.35, -3.90. MS (EI): m/z (%):
388 (100) [M+] 331 (95). Anal. Calcd for C19H24N2OS2Si: C,
58.72; H, 6.22; N, 7.21; S, 16.50. Found: C, 58.72; H, 5.95; N,
6.95; S 16.83.
−
(1) [M-BF4 ]+, 427 (1), 307 (100). Anal. Calcd for
C36H25BF4N2OS2: C, 66.26; H, 3.86; N, 4.29; S, 9.83. Found: C,
66.30; H, 3.70; N, 4.21; S, 9.76.